Kynikos Associates Lp buys $5,904,900 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Kynikos Associates Lp scooped up 20,113 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 49,843 shares of Johnson & Johnson which is valued at $5,904,900.Johnson & Johnson makes up approximately 1.85% of Kynikos Associates Lp’s portfolio.

Other Hedge Funds, Including , Moors Cabot boosted its stake in JNJ in the latest quarter, The investment management firm added 4,717 additional shares and now holds a total of 113,270 shares of Johnson & Johnson which is valued at $13,419,097. Johnson & Johnson makes up approx 2.28% of Moors Cabot’s portfolio.Nn Investment Partners Holdings N.v. reduced its stake in JNJ by selling 402,739 shares or 70.49% in the most recent quarter. The Hedge Fund company now holds 168,583 shares of JNJ which is valued at $20,282,221. Johnson & Johnson makes up approx 0.19% of Nn Investment Partners Holdings N.v.’s portfolio.Ifp Advisors Inc reduced its stake in JNJ by selling 549 shares or 0.44% in the most recent quarter. The Hedge Fund company now holds 123,762 shares of JNJ which is valued at $14,246,244. Johnson & Johnson makes up approx 0.79% of Ifp Advisors Inc’s portfolio.Advisors Capital Management boosted its stake in JNJ in the latest quarter, The investment management firm added 2,333 additional shares and now holds a total of 62,456 shares of Johnson & Johnson which is valued at $7,184,314. Johnson & Johnson makes up approx 0.74% of Advisors Capital Management’s portfolio.Heritage Wealth Advisors reduced its stake in JNJ by selling 666 shares or 4.84% in the most recent quarter. The Hedge Fund company now holds 13,097 shares of JNJ which is valued at $1,519,121. Johnson & Johnson makes up approx 1.07% of Heritage Wealth Advisors’s portfolio.

Johnson & Johnson closed down -0.41 points or -0.35% at $115.36 with 77,17,773 shares getting traded on Monday. Post opening the session at $115.79, the shares hit an intraday low of $114.81 and an intraday high of $115.92 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Oct 18, 2016. Analyst had a consensus of $1.66. The company had revenue of $17820.00 million for the quarter, compared to analysts expectations of $17744.90 million. The company’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.